Table 1 Correlation between SRSF9 expression and the clinicopathological features in 63 CRC patients
From: SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner
Features | SRSF9 expression | χ2 | P value* | |
|---|---|---|---|---|
Low (n, %) | High (n, %) | |||
Cases | 44 | 19 | ||
Gender | ||||
Male | 25 (65.8) | 13 (34.2) | 0.746 | 0.418 |
Female | 19 (76) | 6 (24) | ||
Age (year) | ||||
> 45 | 40 (72.7) | 15 (27.3) | 1.713 | 0.229 |
≤ 45 | 4 (50) | 4 (50) | ||
Tumor size (cm) | ||||
> 5 | 14 (73.7) | 5 (26.3) | 0.191 | 0.770 |
≤ 5 | 30 (68.2) | 14 (31.8) | ||
Grade of differentiation | ||||
Low | 6 (85.7) | 1 (14.3) | 2.270 | 0.321 |
Medium | 23 (59) | 16 (41) | ||
High | 15 (88.2) | 2 (11.8) | ||
Position | ||||
Colon | 31 (66) | 16 (34) | 1.325 | 0.350 |
Rectum | 13 (81.3) | 3 (18.7) | ||
Perineural invasion | ||||
Yes | 9 (69.2) | 4 (30.8) | 0.003 | 1.000 |
No | 35 (70) | 15 (30) | ||
Cancer nodules | ||||
Yes | 11 (68.8) | 5 (31.2) | 0.012 | 1.000 |
No | 33 (70.2) | 14 (29.8) | ||
Tumor depth | ||||
T1–T2 | 2 (100) | 0 (0) | 2.527 | 0.283 |
T3–T4 | 42 (68.9) | 19 (31.1) | ||
Lymph node metastasis | ||||
Positive | 19 (57.6) | 14 (42.4) | 4.950 | 0.031* |
Negative | 25 (83.3) | 5 (16.7) | ||
Dukes stage | ||||
Stage A–B | 25 (89.3) | 3 (10.7) | 9.204 | 0.027* |
Stage C–D | 19 (54.3) | 16 (45.7) | ||